Aclarion Announces Agreement with Weill Cornell Medicine
Aclarion, Inc. (ACON)
Company Research
Source: GlobeNewswire
BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team led by triple-board certified physician and Principal Investigator, Jaspal Ricky Singh, MD, who has earned a national reputation for innovation and excellence. The trial is entitled “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease,” conducted under IRB Protocol No. 22-06024915. The purpose of this initial study is to investigate whether the dose a
Show less
Read more
Impact Snapshot
Event Time:
ACON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACON alerts
High impacting Aclarion, Inc. news events
Weekly update
A roundup of the hottest topics
ACON
News
- Aclarion Announces Agreement with Weill Cornell Medicine [Yahoo! Finance]Yahoo! Finance
- Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician VideoGlobeNewswire
- Aclarion (ACON) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACON&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold"MarketBeat
- Aclarion (ACON) had its price target lowered by Ascendiant Capital Markets from $23.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts [Yahoo! Finance]Yahoo! Finance
ACON
Analyst Actions
- 3/25/26 - Ascendiant Capital
ACON
Sec Filings
- 4/3/26 - Form PRE
- 3/25/26 - Form SCHEDULE
- 3/19/26 - Form 8-K
- ACON's page on the SEC website